Repros Therapeutics Inc (NASDAQ: RPRX)
Repros Therapeutics is having an incredibly positive day today, and for good reason. The company released solid phase 2 clinical trial results with regard to its prime treatment candidate. Today, we’ll talk about the details from the clinical trial, how the market reacted to the news, and what we can expect to see from RPRX moving forward. So, let’s get right to it…
Trade smarter and make more money with Tradespoon!
RPRX Releases Solid Proellex Data
As mentioned above, Repros Therapeutics released solid phase 2 data with regard to Proellex, its lead candidate, yesterday after the closing bell. According to the company, Proellex achieved significant reduction in excessive menstrual bleeding, an important symptom of uterine fibroids, at both tested doses, 6mg and 12mg.
While normal blood loss during a menstrual cycle is considered to be 35 mL, many women suffer from menorrhagia, or excessive menstrual bleeding. This means that the blood loss is over 80 mL during menstrual periods. The phase 2 study by RPRX determined that when a sufficient concentration of Proellex is achieved in circulation, cessation of menses or amenorrhea is achieved. It was found that 79% of women that were treated with Proellex became amenorrheic and had no evidence of dose effect.
Another important piece of data that the study uncovered had to do with fibroids. According to the data, Proellex also helped to reduce fibroids in volume. This was measured through the use of MRI. RPRX determined that Proellex-treated patients saw reductions in fibroid volumen in the amount of 28% while the placebo-treated patients showed a continued increase in size.
How The Market Reacted To The News
As investors, we know that the news moves the market. When positive news is released with regard to a publicly-traded company, we can expect to see gains in the value of that company as a result. Adversely, when negative news is released, stocks will generally see declines. In this particular case, the news released with regard to RPRX was overwhelmingly positive. After all, the Repros Therapeutics phase 2 study met its primary endpoints and helped to validate the effectiveness of Proellex. As a result, we’re seeing strong gains in the value of the stock today. Currently (10:14), RPRX is trading at $2.28 per share after a gain of $0.13 per share, or 6.01%, thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Repros Therapeutics. The reality is that the data released today was incredibly positive and further validates the work that the company is doing with Proellex. Moving forward, the company will move into Phase 3 trials, which, given Phase 1 and Phase 2 results, will likely lead to positive results. So, I’m expecting that, in due time, we will see an RPRX New Drug Application with the FDA for the treatment. In the long run, I see this going incredibly well. The reality is that excessive menstrual bleeding is a commonly occurring issue with little to no treatment options. Therefore, Proellex is a much needed treatment in the medical space. As more and more strong results are released, it seems to me that it’s only a matter of time until we see Proellex generating a profit for RPRX and its investors.
Don’t waste your time! Click here to find winning trades in minutes!
What Do You Think?
Where do you think RPRX is headed moving? Join the discussion at the CNA Finance Forum!
[Image Courtesy of Wikipedia]